Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Preferred Shares (2016 - 2019)

Historic Preferred Shares for Sanara MedTech (SMTI) over the last 5 years, with Q4 2019 value amounting to $11.4 million.

  • Sanara MedTech's Preferred Shares changed 0.0% to $11.4 million in Q4 2019 from the same period last year, while for Dec 2019 it was $11.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $11.4 million for FY2019, which is 0.0% changed from last year.
  • As of Q4 2019, Sanara MedTech's Preferred Shares stood at $11.4 million, which was down 0.0% from $11.4 million recorded in Q3 2019.
  • In the past 5 years, Sanara MedTech's Preferred Shares ranged from a high of $11.4 million in Q4 2018 and a low of $802180.0 during Q4 2015
  • For the 5-year period, Sanara MedTech's Preferred Shares averaged around $5.2 million, with its median value being $863610.0 (2017).
  • As far as peak fluctuations go, Sanara MedTech's Preferred Shares dropped by 9.92% in 2017, and later surged by 122866.03% in 2018.
  • Sanara MedTech's Preferred Shares (Quarter) stood at $802180.0 in 2015, then rose by 6.77% to $856460.0 in 2016, then fell by 0.1% to $855610.0 in 2017, then skyrocketed by 1228.66% to $11.4 million in 2018, then changed by 0.0% to $11.4 million in 2019.
  • Its Preferred Shares was $11.4 million in Q4 2019, compared to $11.4 million in Q3 2019 and $11.4 million in Q2 2019.